Prostate News and Research

RSS

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

Scientists develop novel anticancer drug designed to travel through the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel -- undetected by normal cells -- through the bloodstream until activated by specific cancer proteins.

10 Jul 2012

UTSMC could play key role in operating a proton therapy center for North Texas

UT Southwestern Medical Center, seeking to broaden an already robust array of radiation oncology treatments it offers to patients, potentially could play a key role in operating a state-of-the-art proton therapy center for North Texas being planned and funded by San Diego-based Advanced Particle Therapy (APT).

10 Jul 2012

Prostate patients make moves toward normality

A prompt return to usual daily activity is more likely for patients who have undergone radical prostatectomy if they start performing certain exercises soon after their operation, say researchers.

9 Jul 2012

Presence of SPDEF protein may predict prostate cancers that are unable to metastasize

Prostate cancer doesn't kill in the prostate - it's the disease's metastasis to other tissues that can be fatal. A University of Colorado Cancer Center study published this week in the Journal of Biological Chemistry shows that prostate cancer cells containing the protein SPDEF continue to grow at the same pace as their SPDEF- cousins, but that these SPDEF+ cells are unable to survive at possible sites of metastasis.

8 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.

2 Jul 2012

Blocking AXL protein may prevent resistance to lung cancer drug

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.

2 Jul 2012

UH receives federal grants to pursue projects related to prostate cancer, diabetes and obesity

Researchers at the University of Houston (UH) have been awarded more than $862,000 in federal grants to pursue projects related to prostate cancer, diabetes and obesity. The U.S. Department of Defense (DOD) and National Institutes of Health (NIH) will fund two new prostate cancer projects, while a third NIH grant will support diabetes and obesity research in the UH Center for Nuclear Receptors and Cell Signaling (CNRCS).

28 Jun 2012

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers.

27 Jun 2012

Combination of radiation therapies effectively treat prostate cancer, lower chances of recurrence

A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate cancer and lower the risk of recurrence with minimal radiation exposure to nearby healthy tissue and organs.

27 Jun 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Biological filter to remove estrogens from waste water and drinking water

A biological filter to remove estrogens from waste water and drinking water. The 15 Bielefeld students submitting this project to the 'international Genetically Engineered Machine competition' (iGEM) at the Massachusetts Institute of Technology (MIT) in Boston, USA are setting their sights high.

26 Jun 2012

LLUMC suggests check list with six key attributes for successful proton therapy treatment

When a newly diagnosed cancer patient is considering treatment options, proton therapy might not be the first course that comes to mind. Yet over the past two decades proton therapy has continued to evolve as a viable alternative to chemotherapy and a less-invasive procedure than radiation or surgery, so much so that proton therapy is now considered the preferred course of treatment for many doctors and patients in the fight against cancer.

26 Jun 2012

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the recommendation by the Data Safety Monitoring Board (DSMB) to continue with the global Phase 2b clinical trial with tamibarotene in combination with chemotherapeutical agents as a first-line treatment for patients with advanced non-small-cell lung cancer.

26 Jun 2012

Beckman Coulter announces PMA from FDA for Prostate Health Index

Beckman Coulter, Inc., the leader in prostate cancer diagnostics, announces Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Prostate Health Index (phi), a simple, non-invasive blood test that is 2.5-times more specific in detecting prostate cancer than PSA (prostate-specific antigen) in patients with PSA values in the 4-10 ng/mL range and is proven to reduce the number of prostate biopsies.

From Beckman Coulter Diagnostics 26 Jun 2012

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Medical researchers at the University of Alberta reviewed test results from thousands of patients with various types of cancer and discovered that "disorganized" cancers were more difficult to treat and consistently resulted in lower survival rates.

23 Jun 2012

AUA, AIUM announce collaborative development of urologic ultrasound practice guidelines

The American Institute of Ultrasound in Medicine (AIUM) and American Urological Association (AUA) are proud to announce the collaborative development of practice and training guidelines in the practice of urologic ultrasound which has led to the availability of practice accreditation through the AIUM.

23 Jun 2012

Viewpoints: Berwick says health law puts system 'on the right track;' Mandate's effect overstated; Questions about Axelrod's ties

Obamacare is helping our nation achieve health care that is excellent, accessible to all and affordable. In the 17 months that I led the Centers for Medicare and Medicaid Services (CMS), I saw how this law is helping tens of millions of families and is finally putting our health-care system on the right track.

23 Jun 2012

Prostate News and Research

Arrowhead initiates Adipotide Phase 1 trial in obesity

Scientists develop novel anticancer drug designed to travel through the bloodstream

UTSMC could play key role in operating a proton therapy center for North Texas

Prostate patients make moves toward normality

Presence of SPDEF protein may predict prostate cancers that are unable to metastasize

Cancer Therapeutics reveals proof of concept for second development drug

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

Blocking AXL protein may prevent resistance to lung cancer drug

UH receives federal grants to pursue projects related to prostate cancer, diabetes and obesity

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Combination of radiation therapies effectively treat prostate cancer, lower chances of recurrence

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Biological filter to remove estrogens from waste water and drinking water

LLUMC suggests check list with six key attributes for successful proton therapy treatment

CytRx achieves key milestone in advancing tamibarotene Phase 2b trial for NSCLC

Beckman Coulter announces PMA from FDA for Prostate Health Index

Disorganized cancers more difficult to treat and consistently result in lower survival rates

AUA, AIUM announce collaborative development of urologic ultrasound practice guidelines

Viewpoints: Berwick says health law puts system 'on the right track;' Mandate's effect overstated; Questions about Axelrod's ties

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News